The Filing Desk

Haoxi Health Technology

HAO · Nasdaq · Communication Services · Financials, fiscal 2022 to 2026

HAO · Last close · November 19, 2026
$1.80

Haoxi Health Technology's revenue rose 67.1% to $55 million in fiscal 2026. Its operating margin was −17.6%, down from −6.1% a year earlier. The diluted share count rose 2536.8%.

Haoxi Health Technology Ltd Latest fiscal year ended June 30, 2026 20-F filed September 30, 2026 · 0001213900-26-105242 Updated
Revenue
$55M
67.1%
Operating margin
−17.6%
11.5 pts
Net income
−$10M
$4M a year earlier
Free cash flow
—
 
Return on equity
−54.1%
81.2 pts

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity.

About these figures. Share counts and per-share figures for earlier years are restated for a stock split (40-for-1), so every year is on today's share basis. Haoxi Health Technology is a foreign company: it files an annual report on Form 20-F, prepared under US accounting standards (US GAAP), instead of a 10-K, and no quarterly reports, so this page has fiscal years only. Its shares trade in the US as American depositary shares (ADSs), and one ADS can stand for several ordinary shares, so per-share figures are per ordinary share and the page has no market value, P/E or valuation model. Return on capital for fiscal 2026 is blank: the 10-K's structured data doesn't include intangible assets. Piotroski F-score for fiscal 2026 is blank: the 10-K's structured data doesn't include intangible assets.

What Haoxi Health Technology does

Haoxi Health Technology runs an online advertising business in China, through its Beijing operating company, Haoxi Beijing. It plans, makes, places and fine-tunes online ads, mainly short videos, for advertisers, most of them in healthcare. The ads run on large Chinese platforms such as Toutiao, Douyin, WeChat and Weibo.

It earns money by buying ad space from the platforms, or from their authorized agents, and placing ads for its clients as part of a package that includes planning and production. It uses its own data software, called Bidding Compass, to help decide where ads go. It says it has served about 2,000 advertisers since 2018; in the year to June 2026 it served 565, of which 230 were healthcare companies. Revenue that year was $54.83 million, and the company had a net loss, after profits in the two years before. It competes with other online ad agencies and with traditional media.

The listed company is a holding company outside China. In April 2025 it started a livestreaming agency service, which has not yet brought in sizeable revenue. In 2026 it signed framework agreements to explore AI-based health and marketing projects, and a non-binding letter of intent to buy an online advertising company; no final deal had been signed when it filed its report.

Its biggest risks, as it describes them

  • Advertisers may cut what they spend on online marketing or stop using its services.
  • Its reliance on keeping good relationships with ad platforms and their agents.
  • A few customers bring in a large share of revenue, usually on contracts of a year or less.
  • Unstable revenue and spending that may keep it from making a profit consistently.
  • Chinese government influence over its business, and rules on moving cash out of China.
From Haoxi Health Technology's annual report on Form 20-F, filed September 30, 2026, in our words; the 20-F has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

From fiscal 2023 to 2025, earnings per share grew 6,138.1% a year and net income 97.5% a year. Haoxi Health Technology then lost money in fiscal 2026.

Diluted earnings per share
US$ per ordinary share, fiscal years; loss years in red. One US-listed ADS can stand for several ordinary shares.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY22FY23FY24FY25FY26
Cash and short-term investments017911
Debt incl. finance leases—112—
Net debt (negative means net cash)—−0−6−7—
Net debt to EBITDA—−0.3x−3.2x——
Debt to equity—0.5x0.1x0.1x—
Interest coverage1,304.7x60.5x41.7x−43.5x−184.3x
Current ratio—1.4x4.0x5.0x4.5x
Quick ratio—1.4x4.0x5.0x4.5x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY24FY25FY26
Piotroski F-score—3 of 9—
Rule of 4070.2%——
Altman Z''8.569.165.28
Accruals ratio20.4%39.0%−32.3%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY24FY25FY26
Net income is positivePassPassFail
Cash from operations is positiveFailFailFail
Return on assets rose—FailFail
Cash from operations exceeds net incomeFailFailPass
Debt fell relative to assets—Pass—
Current ratio rosePassPassFail
Share count didn't risePassFailFail
Gross margin roseFailFailFail
Revenue rose relative to assets—FailPass
F-score—3 of 9—
Companies that report no gross profit are scored on the other eight.

Compare

Put Haoxi Health Technology side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Haoxi Health TechnologyFY2667.1%−17.6%————
Dolphin EntertainmentFY259.7%−0.1%−3.6%−0.4%−1.0x4Compare
InuvoFY252.9%−7.8%−3.9%−58.1%—3Compare
TravelzooFY259.3%7.5%6.1%—−1.4x5Compare
IZEA WorldwideFY25−12.9%−6.0%7.6%——8Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

5 years of figures

Fiscal yearFY22FY23FY24FY25FY26
Income statement
Revenue1628483355
Revenue growth—74.7%71.9%−32.4%67.1%
Gross profit12311
Research and development00000
Operating income012−2−10
Net income0114−10
Diluted EPS (US$)0.000.872,701.533,385.53−386.40
Diluted shares (millions)11000
Cash flow
Cash from operations−1−1−1−3−3
Capital expenditure000——
Free cash flow−1−1−1——
Dividends paid00000
Share buybacks00000
Acquisitions00000
Stock-based compensation———0—
Balance sheet at fiscal year end
Cash and short-term investments017911
Debt incl. finance leases—112—
Total assets—4162222
Total liabilities—3444
Shareholders' equity−22111718
Margins and ratios
Gross margin4.0%7.3%5.7%2.8%1.1%
Operating margin1.7%4.2%3.5%−6.1%−17.6%
Net margin1.5%3.4%2.7%11.8%−17.4%
Free cash flow margin−4.2%−3.2%−1.6%——
Rule of 40 (growth + FCF margin)—71.5%70.2%——
Return on capital——37.0%−22.8%—
Return on equity——20.1%27.1%−54.1%
Return on assets——12.9%20.9%−44.2%
Net debt to EBITDA—−0.3x−3.2x——
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Haoxi Health Technology's Form 20-F filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Haoxi Health Technology.